2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170589
    GPR17 antagonist 1 1574405-61-0 98.95%
    GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.
    GPR17 antagonist 1
  • HY-172587
    CB1R Allosteric modulator 5 3019958-44-9 98.35%
    CB1R Allosteric modulator 5 (compound 3) is a selective, and blood-brain barrier (BBB) permeable Cannabinoid receptor type 1 allosteric modulator with a pIC50 of 6.89. CB1R Allosteric modulator 5 attenuates both cocaine-seeking behavior specific to cue-induced reinstatement and cocaine-induced behavioral sensitization without altering locomotor activity.
    CB1R Allosteric modulator 5
  • HY-172941
    VEN-02XX 99.66%
    VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC50 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD).
    VEN-02XX
  • HY-17380R
    (S)-Timolol maleate (Standard) 26921-17-5 99.99%
    (S)-Timolol (maleate) (Standard) is the analytical standard of (S)-Timolol (maleate). This product is intended for research and analytical applications. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
    (S)-Timolol maleate (Standard)
  • HY-175231
    ST171 99.34%
    ST171 is a bitopic 5-HT1AR agonist with an Ki of 0.41  nM. ST171 selectively activates Gi/o signaling pathway and inhibits 5-HT1AR-mediated cAMP accumulation without Gs activation and marginal β-arrestin recruitment. T171 reduces hypersensitivity in chronic neuropathic and inflammatory pain mice model. ST171 can be used for pain research.
    ST171
  • HY-175593
    M6766 696628-90-7 99.43%
    M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC50 of 1.4 μM and a KD of 1.1 μM. M6766 also inhibits ERO1β with an IC50 of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca2+ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke.
    M6766
  • HY-175668
    IDOR-1104-0086 2756581-81-2 98.98%
    IDOR-1104-0086 is an orally active Kv7 potassium channel opener with an EC50 of 210 nM that can cross blood-brain barrier. IDOR-1104-0086 displays strong selectivity against the hERG channel with an IC20 of 25 μM. IDOR-1104-0086 exhibits efficacy in two rodent models of epilepsy and a favorable tolerability profile. IDOR-1104-0086 can used for the study of epilepsy.
    IDOR-1104-0086
  • HY-176550
    ASIC1a antagonist-1 1787243-08-6 98.00%
    ASIC1a antagonist-1 (Compound 5b) is an orthosteric noncompetitive Acid sensing ion channels 1a (ASIC1a) antagonist with an IC50 of 27 nM (pH 6.7). ASIC1a antagonist-1 shifts pH dependence of ASIC1a activation and inhibits its maximal evoked response. ASIC1a antagonist-1 completely inhibits long-term potentiation (LTP) induction in CA3-CA1 pathway. ASIC1a antagonist-1 can be used for brain diseases and pathologies research.
    ASIC1a antagonist-1
  • HY-176710
    PAD-PF2 99.94%
    PAD-PF2 is a PAD family inhibitor, as well as a κ-opioid receptor agonist (EC50 = 7.55 μM) and an M1 muscarinic acetylcholine receptor antagonist (IC50 = 12.3 μM). The IC50 values of PAD-PF2 against PAD1, PAD2, PAD3 and PAD4 are 109 nM, 27.9 nM, 106 nM and 20.1 nM, respectively. PAD-PF2 binds to the common allosteric pocket of PAD1-4, and its inhibitory effects on PAD2 and PAD4 are Ca2+-dependent. PAD-PF2 inhibits protein citrullination in neutrophils. PAD-PF2 is applicable to research related to rheumatoid arthritis, neurodegenerative diseases and cancer.
    PAD-PF2
  • HY-178281
    E0199 931928-13-1 99.89%
    E0199 is a novel potent dual-target KV7/NaV modulator that activates the KV7 channel (KV7.2/7.3 (EC50 = 12.78 nM), KV7.2 (EC50 = 0.50 μM), and KV7.5 (EC50 = 27.14 nM) channels) while simultaneously blocks the NaV1.7 (IC50 = 0.52 μM), NaV1.8 (IC50 = 0.24 μM), and NaV1.9 (IC50 = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research.
    E0199
  • HY-179055
    PROTAC DAPK1 Degrader-1 3063030-38-3
    PROTAC DAPK1 Degrader-1 (Compound CP1) is a DAPK1 PROTAC degrader with a DC50 of 119.6 nM. PROTAC DAPK1 Degrader-1 significantly increased the MDM2 protein level. PROTAC DAPK1 Degrader-1 significantly reduced the levels of cleaved caspase-3 and cleaved PARP in a cell apoptosis model induced by the neurotoxin ceramide, indicating that it effectively inhibits neuronal apoptosis by degrading DAPK1. PROTAC DAPK1 Degrader-1 can be used to study neurological diseases such as cerebral ischemia and traumatic brain injury (pink: DAPK1 ligand (HY-179071); blue: CRBN ligand (HY-10984); black: linker (HY-40171)).
    PROTAC DAPK1 Degrader-1
  • HY-179492
    ACI-19278 3033951-64-0 99.45%
    ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions.
    ACI-19278
  • HY-203012
    NB-7 2665712-31-0 99.82%
    NB-7 (example 12) is a potent and orally active SARM1 inhibitor with an IC50 < 1 μM. NB-7 can be used for neurological disorders research.
    NB-7
  • HY-50682S
    Azeliragon-d9 98.83%
    Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
    Azeliragon-d9
  • HY-B0158S
    Cytidine-d2 40632-25-5 99.86%
    Cytidine-d2 is the deuterium labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
    Cytidine-d2
  • HY-B0163A
    Detomidine hydrochloride 90038-01-0 99.83%
    Detomidine hydrochloride, an imidazole derivative, is a potent α2-adrenergic agonist. Detomidine hydrochloride produces dose-dependent analgesic effects.
    Detomidine hydrochloride
  • HY-B0303R
    Diphenhydramine (Standard) 58-73-1 98.69%
    Diphenhydramine (Standard) is the analytical standard of Diphenhydramine. This product is intended for research and analytical applications. Diphenhydramine is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) .
    Diphenhydramine (Standard)
  • HY-B0459A
    Scopine hydrochloride 85700-55-6 99.69%
    Scopine hydrochloride is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine hydrochloride significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine hydrochloride can be used in targeted therapy research for brain gliomas.
    Scopine hydrochloride
  • HY-B0478R
    Trazodone hydrochloride (Standard) 25332-39-2 99.90%
    Trazodone (hydrochloride) (Standard) is the analytical standard of Trazodone (hydrochloride). This product is intended for research and analytical applications. Trazodone (hydrochloride) (AF-1161) is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.
    Trazodone hydrochloride (Standard)
  • HY-B0722R
    Histamine dihydrochloride (Standard) 56-92-8 99.96%
    Histamine dihydrochloride (Standard) is the analytical standard of Histamine dihydrochloride (HY-B0722). This product is intended for research and analytical applications. Histamine dihydrochloride is the agonist for histamine receptor and a vasodilator. Histamine dihydrochloride is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine dihydrochloride affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
    Histamine dihydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity